Compare OTH & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTH | SERA |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.2M | 77.2M |
| IPO Year | N/A | 2021 |
| Metric | OTH | SERA |
|---|---|---|
| Price | $2.45 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.0K | ★ 86.5K |
| Earning Date | 12-15-2025 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | $600.18 | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $1.95 | $1.37 |
| 52 Week High | $3.75 | $4.17 |
| Indicator | OTH | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 44.66 |
| Support Level | $2.03 | $1.80 |
| Resistance Level | $2.72 | $3.45 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 66.67 | 48.15 |
Off The Hook YS Inc operates as a nationwide leader in the yacht and boat dealership industry, offering a comprehensive suite of services that spans the entire boat value chain. The company operates as two segments: Boat Sales and Azure Funding. Boat Sales includes Specializing in the buying, selling, and wholesaling of yachts and boats, having a boat dealership created to run Yellow Fin sales in Miami; and Azure Funding includes a recreational loan broker and lender providing financing solutions for individuals, dealerships, and brokerages.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.